Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine

Author:

Nygård Mari1,Saah Alfred2,Munk Christian3,Tryggvadottir Laufey45,Enerly Espen1,Hortlund Maria6,Sigurdardottir Lara G.45,Vuocolo Scott2,Kjaer Susanne K.37,Dillner Joakim6

Affiliation:

1. Department of Research, Cancer Registry of Norway, Oslo, Norway

2. Merck & Co., Inc., Kenilworth, New Jersey, USA

3. Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark

4. Icelandic Cancer Registry, Reykjavik, Iceland

5. Faculty of Medicine, University of Iceland, Reykjavik, Iceland

6. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

7. Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Abstract

ABSTRACT This quadrivalent human papillomavirus (qHPV) (HPV6, -11, -16, and -18) vaccine long-term follow-up (LTFU) study is an ongoing extension of a pivotal clinical study (FUTURE II) taking place in the Nordic region. The LTFU study was designed to evaluate the effectiveness, immunogenicity, and safety of the qHPV vaccine (Gardasil) for at least 10 years following completion of the base study. The current report presents immunogenicity data from testing samples of the year 5 LTFU visit (approximately 9 years after vaccination). FUTURE II vaccination arm subjects, who consented to being followed in the LTFU, donated serum at regular intervals and in 2012. Anti-HPV6, -11, -16, and -18 antibodies were detected by the competitive Luminex immunoassay (cLIA), and in addition, serum samples from 2012 were analyzed by the total IgG Luminex immunoassay (LIA) ( n = 1,598). cLIA geometric mean titers (GMTs) remained between 70% and 93% of their month 48 value depending on HPV type. For all HPV types, the lower bound of the 95% confidence interval (CI) for the year 9 GMTs remained above the serostatus cutoff value. The proportion of subjects who remained seropositive based on the IgG LIA was higher than the proportion based on cLIA, especially for anti-HPV18. As expected, the anti-HPV serum IgG and cLIA responses were strongly correlated for all HPV types. Anti-HPV GMTs and the proportion of vaccinated individuals who are seropositive remain high for up to 9 years of follow-up after vaccination.

Publisher

American Society for Microbiology

Subject

Microbiology (medical),Clinical Biochemistry,Immunology,Immunology and Allergy

Reference26 articles.

1. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

2. U.S. Food and Drug Administration. 2006. Approval letter: human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant. U.S. Food and Drug Administration, Washington, DC.

3. Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, Brotons M, Mena M, Cosano R, Munoz J, Bosch J, de Sanjosé S, Castellsagué X. Human papillomavirus and related diseases in the world. Summary Report 2015-04-08. ICO Information Centre on HPV and Cancer (HPV Information Centre). Accessed 24 June 2015. http://www.hpvcentre.net/statistics/reports/XWX.pdf.

4. Early Direct and Indirect Impact of Quadrivalent HPV (4HPV) Vaccine on Genital Warts: a Systematic Review

5. Genital Human Papillomavirus Infection: Incidence and Risk Factors in a Cohort of Female University Students

Cited by 77 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3